USRE32944E - Aromatic carboxylic amide derivatives - Google Patents

Aromatic carboxylic amide derivatives Download PDF

Info

Publication number
USRE32944E
USRE32944E US05/802,486 US80248677A USRE32944E US RE32944 E USRE32944 E US RE32944E US 80248677 A US80248677 A US 80248677A US RE32944 E USRE32944 E US RE32944E
Authority
US
United States
Prior art keywords
acid
compound
group
ome
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/802,486
Inventor
Kozaburo Harita
Yukiyoshi Ajisawa
Kinji Iizuka
Yukihiko Kinoshita
Tetsuhide Kamijo
Michihiro Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Application granted granted Critical
Publication of USRE32944E publication Critical patent/USRE32944E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups

Definitions

  • This invention relates to novel aromatic carboxylic amide derivatives. More particularly, this invention relates to nucleus-substituted cinnamoylaminobenzoic acid derivatives and nucleus-substituted hydrocinnamoylaminobenzoic acid derivatives exhibiting a strong .[.antiallergenic.]. .Iadd.antiallergic .Iaddend.action when administered orally to mammalia including humans.
  • the attached single drawing is a graph showing the change in physiological state with the lapse of time when the compound of this invention is administered to rats experimentally catching asthma.
  • each of R 1 and R 2 is a hydrogen atom or an alkyl group having 1-4 carbon atoms
  • R 3 and R 4 are each a hydrogen atom or together form another chemical bond
  • each X is a hydroxyl group, a halogen atom, an alkyl group having 1-4 carbon atoms and an alkoxy group having 1-4 carbon atoms and may be the same or different
  • n is an integer of 1-3 with the proviso that when two Xs are alkyl or alkoxy groups, they may be connected together to form a ring, can inhibit an experimental anaphylaxis (for example, inflammation of skin caused by an antigen-antibody reaction between reagin and its peculiar antigen) when administered orally to patients.
  • an experimental anaphylaxis for example, inflammation of skin caused by an antigen-antibody reaction between reagin and its peculiar antigen
  • this compound inhibits disruption of mast cells caused by a certain kind of an antigen-antibody reaction (for example, an antigen-antibody reaction between a reaginic antibody and its peculiar antigen) and the subsequent release of chemical mediators from the mast cells.
  • an antigen-antibody reaction for example, an antigen-antibody reaction between a reaginic antibody and its peculiar antigen
  • this compound possesses an .[.antiallergenic.]..Iadd.antiallergic .Iaddend.action and is effective for the therapeutical treatment of diseases caused by allergies, such as asthma, hay fever, .[.articaria.]. .Iadd.urticaria .Iaddend.and atopic dermatitis.
  • this compound was found to be effective to alleviate symptoms in respiration and blood pressure observed in experimental asthma of mammalia.
  • the compounds of this invention are characterized by the presence as a nuclear substituent of at least one substituent selected from hydroxy, alkyl and alkoxy groups and halogen atoms. If the compounds are free of any such substituent, they become weak in .[.antiallergenic.]. .Iadd.antiallergic .Iaddend.action and less valuable for practical use.
  • the nuclear substituent is one or more alkyl or alkoxy groups, they may be linear or branched. Within the range of 1-4 carbon atoms in such groups, no significant change was found in pharmacological effect. Where the nuclear substituents are two alkyl or alkoxy groups, they may be connected together to form a cyclic group.
  • methylenedioxycinnamoylaminobenzoic acid also possesses a strong .[.antiallergenic.]. .Iadd.antiallergic .Iaddend.action.
  • the halogen atoms as nuclear substituents may be chlorine atoms, fluorine atoms and bromine atoms.
  • the compounds having such nuclear halogen atoms are similarly strong in antiallergic action.
  • the number of the nuclear substituents is limited to 1-3. In general, however, pharmacological activity becomes higher as the number of nuclear substituents increases.
  • Compounds carrying as nuclear substituent a hydrophilic group such as a 2,3-dihydroxypropoxy group or a carboxymethoxy group are extremely weak in pharmacological activity.
  • the carboxyl group in the aminobenzoic acid residue may be in any of the 2-, 3- and 4-positions. Salts of compounds having this carboxyl group, such as alkali metal salts are as high in the pharmacological effect as the corresponding compounds having free acid groups, while the compounds in the form of esters with a lower alcohol were found to be inferior in pharmacological activity.
  • Compounds of the general formula (I) can be prepared, for example, by a process wherein a reactive functional derivative of an aromatic carboxylic acid of the general formula: ##STR5## wherein R 1 , R 2 , R 3 , R 4 , X and n have the same meanings as given above, is reacted with an aminobenzoic acid of the formula: ##STR6##
  • an aromatic carboxylic acid or a reactive functional derivative thereof of the above general formula (II) can be reacted withan aminobenzoic ester of the general formula: ##STR7## wherein R 5 is an alkyl group having 1-4 carbon atoms, to provide an aromatic carboxylic amide derivative of the general formula: ##STR8## wherein R 1 , R 2 , R 3 , R 4 , R 5 , X and n have the same meanings as given above, and then this derivative is hydrolyzed to convert the ester group into a free carboxylic group.
  • the compounds of the general formula (I) can be prepared by halogenating a hemiester of malonic acid, reacting the halogenated product in an inert organic solvent such as chloroform with an aminobenzoic acid of the general formula (III) or an ester of the general formula (IV) in the presence of a base, such as a tertiary amine, hydrolyzing the resulting product to form an amidocarboxylic acid and condensing the amidocarboxylic acid according to the Knoevenagel reacton with a nucleus-substituted benzaldehyde corresponding to a carboxylic acid of the general formula (II).
  • Aromatic carboxylic acids of the above general formula (II) are known compounds and can easily be prepared according to methods disclosed in literature.
  • Aromatic carboxylic acids having an unsaturated bond involve the two isomers, i.e., cis-form and .[.transform.]. .Iadd.trans-form.Iaddend., and either may be employed for the process of this invention.
  • aromatic carboxylic acids of the general formula (II) include aromatic unsaturated carboxylic acids, such as 2-, 3- or 4-methylhydrocinnamic acid, 2-, 3- or 4-ethylhydrocinnamic acid, 2-, 3- or 4-propylhydrocinnamic acid, 2-, 3or 4-hydroxyhydrocinnamic acid, 2-, 3- or 4-methoxyhydrocinnamic acid, 2-, 3- or 4-ethoxyhydrocinnamic acid, 2-, 3- or 4-chlorohydrocinnamic acid, 2-, 3- or 4-bromohydrocinnamic acid, 2-, 3- or 4-fluorohydrocinnamic acid, 2,3-dimethylhydrocinnamic acid, 3,4-methylenedioxyhydrocinnamic acid, 60-methyl-4-ethylhydrocinnamic acid and ⁇ -ethyl-2-chlorohydrocinnamic acid; and aromatic unsaturated carboxylic acids
  • reactive functional derivatives of such aromatic carboxylic acids are used as a starting material.
  • examples of such derivatives include carboxylic acid derivatives, such as acid halides, acid anhydrides, mixed acid anhydrides and esters and a reaction product of such carboxylic acid and carbodiimide.
  • carboxylic acid derivatives such as acid halides, acid anhydrides, mixed acid anhydrides and esters and a reaction product of such carboxylic acid and carbodiimide.
  • These reactive functional derivatives can easily be derived from the aromatic carboxylic acids of the general formula (II) according to a usual technique known in this art.
  • the acid chlorides can easily be obtained by refluxing for several hours the aromatic carboxylic acid with thionyl chloride in the absence of any solvent or in dry benzene.
  • the esters can be obtained by heating a given aromatic carboxylic acid with an alcohol in the presence of an acid. .[.The mixed acid halides can be obtained, for example, by reaction with a chloroformic
  • Any of anthranilic acid, m-aminobenzoic acid and p-aminobenzoic acid can be used as the aminobenzoic acid of the general formula (III).
  • Any of anthranilic esters, m-aminobenzoic esters and p-aminobenzoic esters can be used as an aminobenzoic ester of the general formula (IV).
  • the acid halide when used as the reactive functional derivative, the acid halide can be reacted in an inert solvent with an aminobenzoic acid of the general formula (III) or a derivative thereof of the general formula (IV) in the presence of a basic substance.
  • a tertiary organic base such as trimethylamine, triethylamine or pyrdine or an inorganic base such as a caustic alkali, sodium carbonate or potassium carbonate is used as the basic substance.
  • Adequate as the inert solvent are chloroform, methylene chloride, acetone, benzene, toluene, tetrahydrofuran, dioxane and dimethylformamide.
  • reaction may be carried out by using a compound of the general formula (III) in an excess amount, e.g., more than 2 molar proportion to the compound of the general formula (II).
  • the process of this invention is carried out preferably by dissolving a compound of the general formula (III) in a mixture of dry chloroform and dry pyridine respectively in amounts of 5-40 times and 2-15 times as much as the amount of the compound of the general formula (II), adding a solution of a compound of the general formula (II) in dry chloroform to the mixture under cooling and agitation and then refluxing the whole for several hours.
  • reaction product is concentrated under reduced pressure and the residue is poured into water. Hydrochloric acid is then added to the aqueous mixture to make it weakly acidic. The precipitated crystals are collected by filtration and then recrystallized from an adequate organic solvent to obtain the end product.
  • a compound of the general formula (II) is an aromatic carboxylic acid carrying a hydroxyl group on the benzene nucleus
  • such compound is preferably protected in the hydroxyl group with acetyl group or the like prior to the reaction with a compound of the general formula (III).
  • This protective group can be removed in the usual manner.
  • the resulting compound (I) carrying a carboxyl group can be converted according to usual methods to a physiologically acceptable salt thereof.
  • a physiologically acceptable salt thereof for example, an aqueous solution of caustic soda in an equimolar amount can be added to an alcoholic solution of a compound of the general formula (I) and the mixture is warmed for an adequate period of time whereby the compound can easily be converted into its sodium salt.
  • physiologically acceptable salts there can be mentioned, in addition to the sodium salt, alkali metal salts, such as the potassium salt and lithium salt, alkali earth metal salts, such as the magnesium salt and calcium salts, salts with organic amines such as piperidine, triethanolamine and diethylaminoethylamine, and the ammonium salt.
  • aromatic carboxylic amide derivatives of this invention possess a special activity to the effects of an antigen-antibody reaction. Thus, they can be used widely as therapeutic medicaments for diseases caused by allergies.
  • .[.This product was dissolved in 10 ml of chloroform. To this solution were added 10 ml of a 10% aqueous solution of caustic soda and the mixture was warmed at 50° C. to effect hydrolysis of the ester group. After completion of the reaction, the organic phase was separated, washed with water and distilled to remove the solvent whereby.]. .Iadd.this product was then hydrolyzed to the free acid and .Iaddend.2.1 g (yield: 48%) of the end product, i.e., N-(3',4'-dimethoxycinnamoyl)-anthranilic acid, were obtained. This product had a melting point of 211°-213° C.
  • the precipitated crystals were separated by filtration, washed with water and recrystallized from an equivolume mixture of ethanol and water to obtain a yield of 50% 3-(3',4'-dimethoxycinnamoylamino)-benzoic acid having a melting point of 225°-226° C.
  • Wistar male rats weighing 120-150 g were used in this experiment.
  • a reaginic antibody was obtained from rats immunized with egg albumin (EA) dissolved in the pertussis-diphtheria-tetanus vaccine.
  • EA egg albumin
  • Normal rats were sensitized passively with dilution of the antibody by means of intradermal injection.
  • the mixture of antigen (EA) and evans blue was injected intravenously.
  • the animals were killed by a blow on the head 30 minutes after the injection, and then the blue spot resulted from the antigen-antibody reaction was measured photometrically.
  • Chlorphenesin used as a positive control is generally well known as an inhibitor of mast cell disruption resulting from the allergic response.
  • the new aromatic carboxylic amide derivatives of this invention are almost equal to or higher than Chlorphenesin.
  • the nucleus-substituted cinnamoylaminobenzoic acid derivatives are generally stronger in the activity than the nucleus-unsubstituted cinnamoylaminobenzoic acid derivatives.
  • the cinnamoylaminobenzoic acid derivatives nuclearly substituted by a hydrophilic group exhibit substantially no activity.
  • Mesenteric mast cells isolated from normal rats were sensitized passively by means of incubation with rat reaginic antibody at 37° C. After termination of the incubation, the specific antigen (DNP-Ascaris) was added to the incubation medium, then these mast cells in mesentery were fixed with formalin and stained with 0.1% toluidine blue (in acetic acid buffer;pH;4.6). The number of mast cells disrupted as a consequence of the antigen-antibody reaction were counted under a microscope. The number of the mast cells disrupted were also counted without the addition of the specific antigen.
  • DNP-Ascaris DNP-Ascaris
  • test compound dissolved in 1% NaHCO 3 solution was added to the incubation medium at a concentration of 10 -5 g/ml, 5 minutes prior to the treatment of antigen, while only the vehicle was added to the control group.
  • Disodium cromoglycate used as positive control is generally well known as an inhibitor of mast cell disruption resulted in allergic response.
  • the median lethal dose (LD 50 ) of the new aromatic carboxylic acid amide derivatives of this invention were determined in .[.ddstrain.]. .Iadd.dd-strain .Iaddend.male and female mice (6 weeks old) by oral administration and in Wistar strain male and female rats (7 weeks old) by oral and intraperitoneal administration. Each animal selected for the experiment was maintained in an .[.airconditioned.]. .Iadd.air-conditioned .Iaddend.room at a temperature of 22° ⁇ 1° C. and a relative humidity of 55 ⁇ 5% during the full course of the experiment. All animals were fed compressed pellets (CE-2 type produced by Japan CLEA Co.) and water was available ad libitum by bottle. Five groups of ten animals for each administrative route were used.
  • the LD 50 values were calculated from the mortality on the eighth day by the Litchfield-Wilcoxon's method. The results of the tests were as tabulated below.
  • the new aromatic carboxylic amide derivatives and functional derivatives thereof of this invention serve to inhibit not only cutaneous anaphylaxie and release of chemical mediators from mast cells but also experiment asthmatic symptoms caused by an antigen-antibody reaction. These results obviously show that the derivatives of this invention are effective for the therapeutic treatment of allergic diseases including asthma, hay fever, .[.articaria.]. .Iadd.urticaria .Iaddend.and atopic dermatitis.

Abstract

Novel aromatic carboxylic amides of the general formula: ##STR1## wherein each of R1 and R2 is a hydrogen atom or an alkyl group having 1-4 carbon atoms, R3 and R4 are hydrogen atoms or together form another chemical bond, each X is a hydroxyl group, a halogen atom, an alkyl group having 1-4 carbon atoms and an alkoxy group containing 1-4 carbon atoms, and n is an integer of 1-3 with the proviso that when .[.Xs.]. .Iadd.X's .Iaddend.are alkyl or alkoxy groups, they may be connected together to form a ring, as well as pharmaceutically acceptable salts thereof.
These compounds possess a strong antiallergenic action and are thus useful for treatment of asthma, hay fever, .[.anticaria.]. .Iadd.urticaria .Iaddend.and atopic dermatitis.
The above aromatic carboxylic amides can be prepared by reacting a reactive functional derivative of the general formula: ##STR2## where R1, R2, R3, R4, X and n have the same meanings given above, with an aminobenzoic acid of the formula: ##STR3## and, if desired, converting the resulting amide into the corresponding salts.

Description

BACKGROUND OF THE INVENTION
This invention relates to novel aromatic carboxylic amide derivatives. More particularly, this invention relates to nucleus-substituted cinnamoylaminobenzoic acid derivatives and nucleus-substituted hydrocinnamoylaminobenzoic acid derivatives exhibiting a strong .[.antiallergenic.]. .Iadd.antiallergic .Iaddend.action when administered orally to mammalia including humans.
Up to now, disodium cromoglycate was only one drug that inhibits the disruption of mast cells and release therefrom of chemical mediators. However, this compound loses its pharmacological effect when administered orally, and the extent to which this compound is applicable is naturally limited. Thus, development of an antiallergic agent which can display a sufficient therapeutic effect by oral administration has long been demanded in the field of medicine.
On the other hand, .[.nuclei-unsubstituted.]. .Iadd.nucleus-unsubstituted .Iaddend.cinnamoylaminobenzoic acid was already synthetized by Reinicke and publicly known (Liebig's Annalen der Chemie, Vol. 341, pages 94-96). However, this compound shows only a slightly weak .[.antiallergenic.]. .Iadd.antiallergic .Iaddend.effect when adminstered orally to mammalia, and so was hardly useful as a practical medicament.
BRIEF SUMMARY OF THE INVENTION
Accordingly, it is an object of this invention to provide a compound which exhibits a strong .[.antiallergenic.]. .Iadd.antiallergic .Iaddend.action when administered orally to mammalia including humans.
It is another object of this invention to provide a new aromatic carboxylic amide derivative possessing a pharmacological effect.
It is still another object of this invention to provide a nucleus-substituted cinnamoylaminobenzoic acid and a nucleus-substituted hydrocinnamoylaminobenzoic acid and the physiologically acceptable salts thereof.
Other objects, features and advantages of this invention will become apparent as the description proceeds.
The attached single drawing is a graph showing the change in physiological state with the lapse of time when the compound of this invention is administered to rats experimentally catching asthma.
DETAILED DESCRIPTION OF THE INVENTION
It has now been found that a compound of the general formula: ##STR4## wherein each of R1 and R2 is a hydrogen atom or an alkyl group having 1-4 carbon atoms, R3 and R4 are each a hydrogen atom or together form another chemical bond, each X is a hydroxyl group, a halogen atom, an alkyl group having 1-4 carbon atoms and an alkoxy group having 1-4 carbon atoms and may be the same or different, and n is an integer of 1-3 with the proviso that when two Xs are alkyl or alkoxy groups, they may be connected together to form a ring, can inhibit an experimental anaphylaxis (for example, inflammation of skin caused by an antigen-antibody reaction between reagin and its peculiar antigen) when administered orally to patients. It has also been found that this compound inhibits disruption of mast cells caused by a certain kind of an antigen-antibody reaction (for example, an antigen-antibody reaction between a reaginic antibody and its peculiar antigen) and the subsequent release of chemical mediators from the mast cells.
In view of these characteristic properties, it is expected that this compound possesses an .[.antiallergenic.]..Iadd.antiallergic .Iaddend.action and is effective for the therapeutical treatment of diseases caused by allergies, such as asthma, hay fever, .[.articaria.]. .Iadd.urticaria .Iaddend.and atopic dermatitis. In fact, this compound was found to be effective to alleviate symptoms in respiration and blood pressure observed in experimental asthma of mammalia.
The compounds of this invention are characterized by the presence as a nuclear substituent of at least one substituent selected from hydroxy, alkyl and alkoxy groups and halogen atoms. If the compounds are free of any such substituent, they become weak in .[.antiallergenic.]. .Iadd.antiallergic .Iaddend.action and less valuable for practical use. In case the nuclear substituent is one or more alkyl or alkoxy groups, they may be linear or branched. Within the range of 1-4 carbon atoms in such groups, no significant change was found in pharmacological effect. Where the nuclear substituents are two alkyl or alkoxy groups, they may be connected together to form a cyclic group. For example, methylenedioxycinnamoylaminobenzoic acid also possesses a strong .[.antiallergenic.]. .Iadd.antiallergic .Iaddend.action. The halogen atoms as nuclear substituents may be chlorine atoms, fluorine atoms and bromine atoms. The compounds having such nuclear halogen atoms are similarly strong in antiallergic action. The number of the nuclear substituents is limited to 1-3. In general, however, pharmacological activity becomes higher as the number of nuclear substituents increases. Compounds carrying as nuclear substituent a hydrophilic group such as a 2,3-dihydroxypropoxy group or a carboxymethoxy group are extremely weak in pharmacological activity.
In the compounds of this invention, the carboxyl group in the aminobenzoic acid residue may be in any of the 2-, 3- and 4-positions. Salts of compounds having this carboxyl group, such as alkali metal salts are as high in the pharmacological effect as the corresponding compounds having free acid groups, while the compounds in the form of esters with a lower alcohol were found to be inferior in pharmacological activity.
Compounds of the general formula (I) can be prepared, for example, by a process wherein a reactive functional derivative of an aromatic carboxylic acid of the general formula: ##STR5## wherein R1, R2, R3, R4, X and n have the same meanings as given above, is reacted with an aminobenzoic acid of the formula: ##STR6## Alternatively, an aromatic carboxylic acid or a reactive functional derivative thereof of the above general formula (II) can be reacted withan aminobenzoic ester of the general formula: ##STR7## wherein R5 is an alkyl group having 1-4 carbon atoms, to provide an aromatic carboxylic amide derivative of the general formula: ##STR8## wherein R1, R2, R3, R4, R5, X and n have the same meanings as given above, and then this derivative is hydrolyzed to convert the ester group into a free carboxylic group.
Furthermore, the compounds of the general formula (I) can be prepared by halogenating a hemiester of malonic acid, reacting the halogenated product in an inert organic solvent such as chloroform with an aminobenzoic acid of the general formula (III) or an ester of the general formula (IV) in the presence of a base, such as a tertiary amine, hydrolyzing the resulting product to form an amidocarboxylic acid and condensing the amidocarboxylic acid according to the Knoevenagel reacton with a nucleus-substituted benzaldehyde corresponding to a carboxylic acid of the general formula (II).
The aromatic carboxylic acids of the above general formula (II) are known compounds and can easily be prepared according to methods disclosed in literature. Aromatic carboxylic acids having an unsaturated bond involve the two isomers, i.e., cis-form and .[.transform.]. .Iadd.trans-form.Iaddend., and either may be employed for the process of this invention. Examples of the aromatic carboxylic acids of the general formula (II) include aromatic unsaturated carboxylic acids, such as 2-, 3- or 4-methylhydrocinnamic acid, 2-, 3- or 4-ethylhydrocinnamic acid, 2-, 3- or 4-propylhydrocinnamic acid, 2-, 3or 4-hydroxyhydrocinnamic acid, 2-, 3- or 4-methoxyhydrocinnamic acid, 2-, 3- or 4-ethoxyhydrocinnamic acid, 2-, 3- or 4-chlorohydrocinnamic acid, 2-, 3- or 4-bromohydrocinnamic acid, 2-, 3- or 4-fluorohydrocinnamic acid, 2,3-dimethylhydrocinnamic acid, 3,4-methylenedioxyhydrocinnamic acid, 60-methyl-4-ethylhydrocinnamic acid and β-ethyl-2-chlorohydrocinnamic acid; and aromatic unsaturated carboxylic acids, such as 2- or 3- or 4-methylcinnamic acid, 2-, 3- or 4-ethylcinnamic acid, 2-, 3- or 4 -propylcinnamic acid, 2-, 3- or 4-butylcinnamic acid, 2-, 3- or 4-hydroxycinnamic acid, 2-, 3- or 4-methoxycinnamic acid, 2-, 3- or 4-ethoxycinnamic acid, 2-, 3- or 4-propoxycinnamic acid, 2-, 3- or 4-propoxycinnamic acid, 2-, 3- or 4-chlorocinnamic acid, 2-, 3- or 4-fluorocinnamic acid, 2-, 3- or 4-bromocinnamic acid, 2-methyl-3-ethylcinnamic acid, 3,4-dimethylcinnamic acid, 2,3-dimethoxycinnamic acid, 3,4-dimethoxycinnamic acid, α-methyl-3,4-dimethoxycinnamic acid, β-methyl-3,4-dimethoxycinnamic acid, 3,4-diethoxycinnamic acid, 2,4,5-trimethoxycinnamic acid, 2,4-dichlorocinnamic acid, 3,4-methylenedioxycinnamic acid and 3,4-trimethylenecinnamic acid. In the process of this invention, reactive functional derivatives of such aromatic carboxylic acids are used as a starting material. Examples of such derivatives include carboxylic acid derivatives, such as acid halides, acid anhydrides, mixed acid anhydrides and esters and a reaction product of such carboxylic acid and carbodiimide. These reactive functional derivatives can easily be derived from the aromatic carboxylic acids of the general formula (II) according to a usual technique known in this art. For example, the acid chlorides can easily be obtained by refluxing for several hours the aromatic carboxylic acid with thionyl chloride in the absence of any solvent or in dry benzene. The esters can be obtained by heating a given aromatic carboxylic acid with an alcohol in the presence of an acid. .[.The mixed acid halides can be obtained, for example, by reaction with a chloroformic ester..].
Any of anthranilic acid, m-aminobenzoic acid and p-aminobenzoic acid can be used as the aminobenzoic acid of the general formula (III). Any of anthranilic esters, m-aminobenzoic esters and p-aminobenzoic esters can be used as an aminobenzoic ester of the general formula (IV).
The above-mentioned amidation can be carried out according to methods known per se. For example, when an acid halide is used as the reactive functional derivative, the acid halide can be reacted in an inert solvent with an aminobenzoic acid of the general formula (III) or a derivative thereof of the general formula (IV) in the presence of a basic substance. In this case, a tertiary organic base such as trimethylamine, triethylamine or pyrdine or an inorganic base such as a caustic alkali, sodium carbonate or potassium carbonate is used as the basic substance. Adequate as the inert solvent are chloroform, methylene chloride, acetone, benzene, toluene, tetrahydrofuran, dioxane and dimethylformamide.
Instead of using such a basic substance, the reaction may be carried out by using a compound of the general formula (III) in an excess amount, e.g., more than 2 molar proportion to the compound of the general formula (II).
The process of this invention is carried out preferably by dissolving a compound of the general formula (III) in a mixture of dry chloroform and dry pyridine respectively in amounts of 5-40 times and 2-15 times as much as the amount of the compound of the general formula (II), adding a solution of a compound of the general formula (II) in dry chloroform to the mixture under cooling and agitation and then refluxing the whole for several hours.
The reaction product is concentrated under reduced pressure and the residue is poured into water. Hydrochloric acid is then added to the aqueous mixture to make it weakly acidic. The precipitated crystals are collected by filtration and then recrystallized from an adequate organic solvent to obtain the end product.
In case a compound of the general formula (II) is an aromatic carboxylic acid carrying a hydroxyl group on the benzene nucleus, such compound is preferably protected in the hydroxyl group with acetyl group or the like prior to the reaction with a compound of the general formula (III). This protective group can be removed in the usual manner.
The resulting compound (I) carrying a carboxyl group can be converted according to usual methods to a physiologically acceptable salt thereof. For example, an aqueous solution of caustic soda in an equimolar amount can be added to an alcoholic solution of a compound of the general formula (I) and the mixture is warmed for an adequate period of time whereby the compound can easily be converted into its sodium salt. As examples of such physiologically acceptable salts there can be mentioned, in addition to the sodium salt, alkali metal salts, such as the potassium salt and lithium salt, alkali earth metal salts, such as the magnesium salt and calcium salts, salts with organic amines such as piperidine, triethanolamine and diethylaminoethylamine, and the ammonium salt.
The aromatic carboxylic amide derivatives of this invention possess a special activity to the effects of an antigen-antibody reaction. Thus, they can be used widely as therapeutic medicaments for diseases caused by allergies.
This invention will be illustrated in more detail by way of examples wherein none of the melting points of the products have been corrected.
EXAMPLE 1
In a mixture of 20 ml of dry chloroform and 10 ml of dry pyridine were dissolved 2.6 g of 4-aminobenzoic acid. To this mixture were added dropwise under cooling 20 ml of dry chloroform containing 3.2 g of 4-acetoxycinnamoyl chloride. The mixture was heated under reflux for 2 hours and the reaction mixture was concentrated under reduced pressure. The residue was poured into water and hydrochloric acid was then added to make the liquid weakly acidic. The precipitated crystals were collected by filtration and recrystallized from alcohol to yield 2.9 g of 4-(4'-acetoxycinnamoylamino)-benzoic acid. M.P.=305°-307° C. (with decomposition).
A mixture of 2.7 g of 4-(4'-acetoxycinnamoylamino)benzoic acid and 50 ml of a 10% aqueous solution of sodium hydroxide was warmed for one hour, cooled and then weakly acidified with hydrochloric acid. The precipitated crystals were collected by filtration and recrystallized from aqueous alcohol whereby 1.75 g of 4-(4'-hydroxycinnamoylamino)benzoic acid were obtained. M.P.=306°-307° C. (with decomposition).
Elementary analysis as C16 H13 O4 N
______________________________________                                    
       C           H       N                                              
______________________________________                                    
Calc.    67.84%        4.63%   4.95%                                      
Found    67.69         4.56    4.72                                       
______________________________________                                    
IR-absorption spectra (KBr)
νCO: 1690, 1670 cm-1
NMR spectra (d6 - DMSO)
δ6.75, 7.58 (q, 2H J=17 Hz, olefinic hydrogen)
6.90, 7.52 (q, 4H J=8 Hz, hydroxy group-substituted aromatic ring hydrogen)
7.87, 7.96 (q, 4H J=9 Hz, amino group-substituted aromatic ring hydrogen)
.[.9.7-10.3 (broad 1H, amido hydrogen).].
10.4 (s, 1H, carboxylic acid hydrogen)
.Badd.3.5-4.5 (broad, 1H, phenolic hydroxyl group hydrogen).]..Baddend.
Mass spectra M+ 283, m/e 238, 147, 119.
In 100 ml of warmed ethanol were dissolved 1.42 g of 4-(4'-.[.hydroxy cinnamoylamino.]..Iadd.hydroxycinnamoylamino.Iaddend.)benzoic acid. To this solution was added a solution of 0.21 g of sodium hydroxide in 3 ml of water and the mixture was warmed for 30 minutes, cooled and then filtered to collect crystals precipitated. 1.20 Grams of sodium salt of 4-(4'hydroxycinnamoylamino)benzoic acid were thus obtained.
The following compounds can be prepared in a similar manner:
______________________________________                                    
 ##STR9##                                                                 
Comp                         Pos.           Recrys.                       
No    n     X        R.sub.1                                              
                         R.sub.2                                          
                             COOH  M.P. (°C.)                      
                                            Solvent                       
______________________________________                                    
1     1     4'-OH    H   H   2     220.5-221.5                            
                                            Aq. Alc.                      
2     1     4'-OH    H   H   4     306-307  "                             
                                   (w/decomp.)                            
3     1     2'-OH    H   H   2     230-231  "                             
4     1     2'-OH    H   H   3     267-268  "                             
5     2     2'-OH    H   H   2     206-208  "                             
            3'-OMe                                                        
6     2     2'-OH    H   H   4        307-307.5                           
                                            "                             
            3'-OMe                 (w/decomp.)                            
7     2     4'-OH    H   H   2     230-232  Alcohol                       
            3'-OMe                                                        
8     2     4'-OH    H   H   3       238-239.5                            
                                            Aq. Alc.                      
            3'-OMe                                                        
9     2     3'-OH    H   H   2     204-206  "                             
            4'-OH                  (w/decomp.)                            
10    3     2'-Br    H   H   2     249-250  "                             
            4'-OH                                                         
            5'-OMe                                                        
11    2     4'-OH    H   H   4     250-251  "                             
            3'-OMe                                                        
______________________________________                                    
EXAMPLE 2
In a similar manner except that 3-methoxy-4-acetoxyhydrocinnamoyl chloride was used in place of the 4-acetoxycinnamoyl chloride used in Example 1 for reaction with 3-aminobenzoic acid and the reaction product was hydrolyzed, 3-(3'-methoxy-4'-.[.hydroxyhydrocinnamoyl amino.]..Iadd.hydroxyhydrocinnamoylamino.Iaddend.)benzoic acid was obtained. After recrystallization from an aqueous alcohol, this product had a melting point of .[.218'220° C..]. .Iadd.218°-220° C.
EXAMPLE 3
4.3 Grams of 4-aminobenzoic acid were dissolved in a mixture of 100 ml of dry chloroform and 19 g of dry pyridine. To this mixture were added dropwise under cooling 100 ml of a dry chloroform solution containing 5.4 g of 3,4-dimethoxycinnamoyl chloride. The mixture was heated under reflux for 1.5 hours and the reaction mixture was then concentrated under reduced pressure. The residue was poured into water and hydrochloric acid was then added to make the liquid weakly acidic. The precipitated crystals were collected by filtration and recrystallized from an alcohol whereby 5.6 g of 4-(3',4'-dimethoxycinnamoylamino)benzoic acid were obtained. M.P.=267°-9° C.
Elementary analysis as C18 H17 O5 N
______________________________________                                    
       C           H       N                                              
______________________________________                                    
Calc.    66.05%        5.24%   4.28%                                      
Found    66.00         5.12    4.14                                       
______________________________________                                    
IR-absorption spectra (KBr)
νCO: 1690, 1665 cm-1
νNH: 3320 cm-1
NMR spectra (d6 - DMSO)
δ6.78, 7.62 (q, 2H, J=16 Hz olefinic hydrogen)
7.0-7.3 (m, 3H, methoxy-substituted aromatic ring hydrogen)
7.85, 7.97 (q, 4H, J=9 Hz, amino-substituted aromatic ring hydrogen)
10.4 (s, 1H, carboxylic acid hydrogen)
11.5-12.7 (broad 1H amido hydrogen)
3.81, 3.83 (s, s, 6H, methoxy hydrogen)
Mass spectra
M+ 327
m/e 282, 191, 163.
1.5 Grams of 4-(3',4'-dimethoxycinnamoylamino)benzoic acid were dissolved in 150 ml of warmed ethanol and an aqueous alcoholic solution (ethanol 2:water 1) of an equimolar amount of sodium hydroxide was added whereby white crystals precipitated out. The crystals were collected by filtration and dried under reduced pressure to obtain 1.0 g. of sodium 4-(3',4'-dimethoxycinnamoylamino)benzoate.
In a similar manner, the following compounds can be prepared:
______________________________________                                    
 ##STR10##                                                                
Comp                            Pos.  M.P.  Recrys.                       
No    n     X         R.sub.1                                             
                           R.sub.2                                        
                                COOH  (°C.)                        
                                            Solvent                       
______________________________________                                    
12    1     4'-OMe    H    H    2     195-  Aq. Alc.                      
                                      198                                 
13    1     4'-OMe    H    H    4     292-  Alcohol                       
                                      294                                 
14    1     3'-OMe    H    H    2     183-  Aq. Alc.                      
                                      185                                 
15    1     3'-OMe    H    H    3     213-  "                             
                                      216                                 
16    1     4'-OMe    CH.sub.3                                            
                           H    2     171-  "                             
                                      172                                 
17    1     4'-OMe    CH.sub.3                                            
                           H    4     262-  Alcohol                       
                                      263                                 
18    1     4'-OMe    H    CH.sub.3                                       
                                2     188-  Aq. Alc.                      
                                      191                                 
19    1     4'-OMe    H    CH.sub.3                                       
                                3     244-  Alcohol                       
                                      246                                 
20    1     4'-Cl     H    H    2     195-  Aq. Alc.                      
                                      203                                 
21    1     4'-Cl     H    H    4     332-  "                             
                                      335                                 
                                      (w/de-                              
                                      comp.)                              
22    1     2'-Cl     H    H    2     184.5-                              
                                            "                             
                                      188.5                               
23    1     2'-Cl     H    H    3     289-  "                             
                                      291                                 
24    1     4'-Cl     CH.sub.3                                            
                           H    2     183-  "                             
                                      185                                 
25    1     4'-Cl     CH.sub.3                                            
                           H    4     294-  Alcohol                       
                                      295                                 
26    1     4'-Cl     H    CH.sub.3                                       
                                3     244-  "                             
                                      244.5                               
27    1     4'-Cl     H    CH.sub.3                                       
                                2     208.5-                              
                                            Chlo.                         
                                      210.5                               
28    1     4'-F      H    H    2     200-  Alcohol                       
                                      201.5                               
29    1     3'-F      H    H    2     194-  "                             
                                      195.5                               
30    1     2'-F      H    H    2     193-  "                             
                                      194.5                               
31    2     2'-OMe    H    H    2     198.5-                              
                                            Aq. Alc.                      
            3'-OMe                    200                                 
32    2     2'-OMe    H    H    4     261-  Alcohol                       
            3'-OMe                    263.5                               
33    2     3'-OMe    H    H    2     211-  Chlo.                         
            4'-OMe                    213                                 
34    2     3'-OMe    H    H    3     225-  Alcohol                       
            4'-OMe                    226                                 
35    2     3'-OMe    H    H    4     267-  "                             
            4'-OMe                    269                                 
36    2     3'-OMe    CH.sub.3                                            
                           H    2     173-  Aq. Alc.                      
            4'-OMe                    175                                 
37    2     3'-OMe    CH.sub.3                                            
                           H    3     163-  "                             
            4'-OMe                    164                                 
38    2     3'-OMe    CH.sub.3                                            
                           H    4     241-  Alcohol                       
            4'-OMe                    243                                 
39    2     3'-OMe    H    CH.sub.3                                       
                                2     169-  Aq. Alc.                      
            4'-OMe                    172                                 
40    2     3'-OMe    H    CH.sub.3                                       
                                3     203.5-                              
                                            "                             
            4'-OMe                    204.5                               
41    2     3'-OMe    H    CH.sub.3                                       
                                4     225.5-                              
                                            Meth.                         
            4'-OMe                    227.5                               
42    1     4'-CH.sub.3                                                   
                      H    H    2     210.5-                              
                                            Aq. Alc.                      
                                      213                                 
43    1     4'-CH.sub.3                                                   
                      H    H    4     308-  "                             
                                      310                                 
44    1     4'-Cl     C.sub.2 H.sub.5                                     
                           H    2     201-  "                             
                                      204                                 
45    1     4'-OMe    H    C.sub.2 H.sub.5                                
                                4     220-  "                             
                                      221.5                               
46    1     4'-Br     H    H    2     222-  "                             
                                      225                                 
47    1     4'-Br     H    H    4     >330  Alcohol                       
48    2     3'-OEt    H    H    2     185-  Aq. Alc.                      
            4'-OEt                    187                                 
49    2     3'-OEt    H    H    4     253-  "                             
            4'-OEt                    256                                 
50    2     4'-OEt    H    H    2     210.5-                              
                                            "                             
            3'-OMe                    212.5                               
51    2     4'-OEt    H    H    3     219-  "                             
            3'-OMe                    222                                 
52    3     2'-OMe    H    H    2     206-  "                             
            4'-OMe                    208                                 
            5'-OMe                                                        
53    2     3',4'-    H    H    2     209-  Alcohol                       
            methylene-                210.5                               
            dioxy                                                         
54    1     3'-Cl     H    H    2     194-  Aq. Ace.                      
                                      196                                 
55    2     4'-On-    H    H    2     172-  Chlo.                         
            Pro                       177                                 
            3'-OMe                                                        
56    2     4'-Oi-    H    H    2     76-78 "                             
            Pro                                                           
            3'-OMe                                                        
57    1     3-Oi-     H    H    2     121-  Benz/                         
            Pro                       124   Pet.                          
                                            Ether                         
58    1     4'-Oi-    H    H    2     140-  Benz./                        
            Pro                       142.5 Pet.                          
                                            Ether                         
59    1     4'-i-Pro  H    H    2     153-  Iprop.                        
                                      156   Ether                         
60    2     2'-OMe    H    H    3     238-  Alc./                         
            3'-OMe                    240   Ligroin                       
61    2     2'-OMe    H    H    2     188-  Aq. Alc.                      
            4'-OMe                    191                                 
62    2     2'-OMe    H    H    2     181-  "                             
            5'-OMe                    183                                 
______________________________________                                    
EXAMPLE 4
In a similar manner except that the cinnamoyl chloride used in Example 3 was replaced by the corresponding hydrocinnamoyl chloride, the following compounds could be prepared:
______________________________________                                    
 ##STR11##                                                                
Comp                          Pos.          Recrys.                       
No    n     X        R.sub.1                                              
                         R.sub.2                                          
                              COOH  M.P. (°C.)                     
                                            Solvent                       
______________________________________                                    
63    1     3'-OMe   H   H    2       192-194.5                           
                                            Aq. Alc.                      
64    2     3'-OMe   H   H    3     176-177 Alc./                         
            4'-OMe                          Benz.                         
65    1     4'-Cl    H   H    4     278.5-280.5                           
                                            Aq. Alc.                      
66    1     4'-OMe   H   CH.sub.3                                         
                              4     222-226 "                             
67    2     3'-OMe   H   H    2       136-137.5                           
                                            Benzene                       
            4'-OMe                                                        
______________________________________                                    
EXAMPLE 5
4 Grams of 3,4-dimethoxycinnamic acid was dissolved in 20 ml of dry pyridine. To this solution were added under cooling with ice and agitation 2 g of benzenesulfonyl chloride whereby a red orange precipitate was formed. The reaction mixture was stirred for about one hour and then 2 g of methyl anthranilate were added to the mixture under cooling with ice. The mixture was stirred for 2 hours at room temperature to complete the reaction. After completion of the reaction, the reaction mixture was concentrated and the residue was taken up in about 10 ml of chloroform. The solution was washed first with a 10% aqueous solution of caustic soda, then with a 10% aqueous solution of hydrochloric acid and finally with water and then distilled to remove chloroform whereby crystals of N-(3',4'-dimethoxycinnamoyl)-anthranilic acid methyl ester were obtained.
.[.This product was dissolved in 10 ml of chloroform. To this solution were added 10 ml of a 10% aqueous solution of caustic soda and the mixture was warmed at 50° C. to effect hydrolysis of the ester group. After completion of the reaction, the organic phase was separated, washed with water and distilled to remove the solvent whereby.]. .Iadd.this product was then hydrolyzed to the free acid and .Iaddend.2.1 g (yield: 48%) of the end product, i.e., N-(3',4'-dimethoxycinnamoyl)-anthranilic acid, were obtained. This product had a melting point of 211°-213° C.
When the condensation reaction was carried out under similar conditions except that 1.9 g of anthranilic acid were used in place of methyl anthranilate used in this example, 2.0 g of N-(3',4'-dimethoxycinnamoyl)-anthranilic acid could directly be obtained.
EXAMPLE 6
2 Grams of 3,4-dimethoxycinnamic acid were dissolved in a mixture of 20 ml of dry dimethylformamide and 1.5 g of triethylamine. To this solution was added under ice cooling and agitation 1.1 g of ethyl chlorocarbonate and the mixture was then reacted for one hour. To this mixture were added 10 ml of dimethylformamide containing 1.5 g of 3-aminobenzoic acid and the mixture was stirred for 2 hours. After completion of the reaction, the reaction liquid was concentrated approximately to 1/2 volume and poured into an aqueous solution of hydrochloric acid. The precipitated crystals were separated by filtration, washed with water and recrystallized from an equivolume mixture of ethanol and water to obtain a yield of 50% 3-(3',4'-dimethoxycinnamoylamino)-benzoic acid having a melting point of 225°-226° C.
EXAMPLE 7
To a mixture of 20 ml of dry dioxane and 0.7 g of dry pyridine were added 2 g of 3,4-dimethoxycinnamic acid, 1.6 g of phosphorus oxychloride and 1.6 g of methyl anthranilate. The mixture was heated under reflux for 2 hours to effect reaction. After completion of the reaction, the reaction mixture was concentrated and the residue was dissolved with heating in ethanol and then cooled whereby crystals were precipitated. The crystals were separated by filtration and treated in a manner similar to that described in Example 5 to effect hydrolysis of the ester group. The product was recrystallized from chloroform to obtain 2 g of N-(3',4'-dimethoxycinnamoyl)-anthranilic acid having a melting point of 211°-213° C.
EXAMPLE 8--"Homologous Passive Cutaneous Anaphylaxis in Rats"
Wistar male rats weighing 120-150 g were used in this experiment. A reaginic antibody was obtained from rats immunized with egg albumin (EA) dissolved in the pertussis-diphtheria-tetanus vaccine. Normal rats were sensitized passively with dilution of the antibody by means of intradermal injection. After 48 hours of the sensitization, the mixture of antigen (EA) and evans blue was injected intravenously. The animals were killed by a blow on the head 30 minutes after the injection, and then the blue spot resulted from the antigen-antibody reaction was measured photometrically.
A given test compound dissolved in 1% NaHCO3 solution was administered in a dose of 200 mg/kg orally 2 hours prior to the injection of antigen, while only the vehicle solution was administered to the control group. Chlorphenesin used as a positive control is generally well known as an inhibitor of mast cell disruption resulting from the allergic response.
The efficacy of the test compounds to inhibit the homologous passive cutaneous anaphlaxis was compared with the value (%) calculated using the following formula: ##EQU1## wherein A stands for the amount of leaked dye in control group and B for the amount of leaked dye in the group administered with a given test compound.
It seems likely that the homologous passive cutaneous anaphylaxis in rats is useful to determine whether a test compound inhibits an allergic response or not.
The results of the tests were as shown below.
______________________________________                                    
Test                          Inhibi-                                     
No.    Compound               tion (%)                                    
______________________________________                                    
1      Control                0                                           
2      Chlorophenesin         36.7                                        
3      N--cinnamoyl-anthranilic acid                                      
                              16.7                                        
4      3-(cinnamoylamino)-benzoic acid                                    
                              10.0                                        
5      4-(cinnamoylamino)-benzoic acid                                    
                              7.0                                         
6      N--(4'-hydroxycinnamoyl)-anthranilic                               
                              36.7                                        
       acid                                                               
7      3-(3'-methoxycinnamoylamino)-benzoic                               
                              45.0                                        
       acid                                                               
8      N--(2'-chlorocinnamoyl)-anthranilic                                
                              60.2                                        
       acid                                                               
9      N--(4'-chlorocinnamoyl)-anthranilic                                
                              69.4                                        
       acid                                                               
10     4-(4'-bromocinnamoylamino)-benzoic                                 
                              32.3                                        
       acid                                                               
11     N--(3'-fluorocinnamoyl)-anthranilic                                
                              47.5                                        
       acid                                                               
12     N--(4'-methylcinnamoyl)-                                           
                              54.0                                        
       anthranilic acid                                                   
13     4-(2'-hydroxy-3'-methoxycinnamoyl-                                 
                              33.5                                        
       amino)-benzoic acid                                                
14     N--(2',3'-dimethoxycinnamoyl)-                                     
                              56.8                                        
       anthranilic acid                                                   
15     3-(2',3'-dimethoxycinnamoyl-                                       
                              41.1                                        
       amino)-benzoic acid                                                
16     N--3'-methoxy-4'-n-propoxycin-                                     
                              52.2                                        
       namoyl)-anthranilic acid                                           
17     N--(3'-methoxy-4'-isopropoxycin-                                   
                              47.1                                        
       namoyl)-anthranilic acid                                           
18     N--(3',4'-dimethoxycinnamoyl)                                      
                              46.1                                        
       anthranilic acid                                                   
19     N--(2',4',5'-trimethoxycinnamoyl)-                                 
                              56.8                                        
       anthranilic acid                                                   
20     N--(3',4'-dimethoxylhydrocinnamoyl)-                               
                              55.4                                        
       anthranilic acid                                                   
21     N--(3',4'-dimethoxy-β-methylcin-                              
                              66.2                                        
       namoyl)-anthranilic acid                                           
22     N--[3'-methoxy-4'-(2,3-dihydroxy-                                  
                              9.0                                         
       propoxy)-cinnamoyl]-anthranilic                                    
       acid                                                               
23     N--(3'-methoxy-4'-carboxylmethoxy-                                 
                              0                                           
       cinnamoyl)-anthranilic acid                                        
______________________________________                                    
The above results obviously show that in pharmacological activity, the new aromatic carboxylic amide derivatives of this invention are almost equal to or higher than Chlorphenesin. The nucleus-substituted cinnamoylaminobenzoic acid derivatives are generally stronger in the activity than the nucleus-unsubstituted cinnamoylaminobenzoic acid derivatives. However, the cinnamoylaminobenzoic acid derivatives nuclearly substituted by a hydrophilic group exhibit substantially no activity.
EXAMPLE 9--"Effect on the Disruption of the Sensitized Mast Cells"
Mesenteric mast cells isolated from normal rats were sensitized passively by means of incubation with rat reaginic antibody at 37° C. After termination of the incubation, the specific antigen (DNP-Ascaris) was added to the incubation medium, then these mast cells in mesentery were fixed with formalin and stained with 0.1% toluidine blue (in acetic acid buffer;pH;4.6). The number of mast cells disrupted as a consequence of the antigen-antibody reaction were counted under a microscope. The number of the mast cells disrupted were also counted without the addition of the specific antigen.
A given test compound dissolved in 1% NaHCO3 solution was added to the incubation medium at a concentration of 10-5 g/ml, 5 minutes prior to the treatment of antigen, while only the vehicle was added to the control group. Disodium cromoglycate used as positive control is generally well known as an inhibitor of mast cell disruption resulted in allergic response.
The efficacy of the test compounds to inhibit the mast cell disruption was compared with the value (%) calculated using the following formula: ##EQU2## wherein P stands for the percentage of disrupted mast cells in the control group, Q for the percentage of mast cells disrupted spontaneously and R for the percentage of disrupted mast cells in the group treated with a given test compound.
It seems likely that this method is useful to determine whether a given test compound inhibits the disruption of mast cells and the subsequent release of chemical mediators from mast cells or not.
The results of the tests were as tabulated below.
______________________________________                                    
Test                        Inhibi-                                       
No.      Compound           tion (%)                                      
______________________________________                                    
1        Control             0                                            
2        Disodium cromoglycate                                            
                            16                                            
3        N--(3',4'-dimethoxycinnamoyl)-                                   
                            33                                            
         anthranilic acid                                                 
4        N--(3',4'-dimethoxy-β-methyl-                               
                            45                                            
         cinnamoyl)-anthranilic acid                                      
5        3-3'-methoxycinnamoylamino)-                                     
                            18                                            
         benzoic acid                                                     
6        N--(3'-methoxy-4'-n-propoxycin-                                  
                            37                                            
         namoyl)-anthranilic acid                                         
______________________________________                                    
The above results obviously show that in pharmacological activity the novel aromatic carboxylic amide derivatives of this invention are almost equal to or higher than disodium cromoglycate.
EXAMPLE 10--"Experimental Asthma in Rats"
Twenty normal male rats weighing 120-150 g were divided into four groups each consisting of five rats. .[.5 Milliliters of a 1% aqueous solution of NaHCO3 containing 2-(3',4'-dimethoxycinnamolyamino)-benzoic acid (Compound 33 above) in a dose of 0 mg/kg, 5 mg/kg. 10 mg/kg or 20 mg/kg were orally administered to rats in each group respectively. After the lapse of two hours of the administration, all of the rats were sensitized passively by means of the intravenous injection of rat reaginic antibody. After a lapse of 24 hours of sensitization, both the trachea and the common carotide artery were canulated. The rate and volume of respiration and systemic blood pressure were recorded simultaneouly on the polygraph. The results of these tests are shown in the annexed drawing. The asthmatic symptoms resulting from the injection of the specific antigen (DNP-Ascaris) were observed..]. .Iadd.5 Millimeters of a 1% aqueous solution of NaHCO3 containing 2-(3',4'-dimethoxycinnamoylamino)-benzoic acid (Compound 33 above) in a dose of 0 mg/kg, 5 mg/kg., 10 mg/kg or 20 mg/kg were orally administered to rats in each group respectively. After the lapse of two hours of the administration and after a lapse of 24 hours of sensitization, both the trachea and the common carotide artery were canulated. The rate and volume of respiration and systemic blood pressure were recorded simultaneously on the polygraph. The results of these tests are shown in the annexed drawing. The asthmatic symptoms resulting from the injection of the specific antigen (DNP-Ascaris) were observed..Iaddend.
As is evident from the drawing, decrease in the rate of respiration was observed in the control after a lapse of three minutes from the injection of antigen. On the other hand, Compound No. 33 showed inhibition at a dose of 5 mg/kg or more. Concerning the decrease in the volume of respiration, this compound showed inhibition in a dose of 10 mg/kg or more. This compound showed no inhibiting effect on depression of blood pressure just after the challenge but showed an inhibiting effect on the subsesquent depression.
EXAMPLE .[.10.]. .Iadd.11.Iaddend."Acute Toxicity"
The median lethal dose (LD50) of the new aromatic carboxylic acid amide derivatives of this invention were determined in .[.ddstrain.]. .Iadd.dd-strain .Iaddend.male and female mice (6 weeks old) by oral administration and in Wistar strain male and female rats (7 weeks old) by oral and intraperitoneal administration. Each animal selected for the experiment was maintained in an .[.airconditioned.]. .Iadd.air-conditioned .Iaddend.room at a temperature of 22°±1° C. and a relative humidity of 55±5% during the full course of the experiment. All animals were fed compressed pellets (CE-2 type produced by Japan CLEA Co.) and water was available ad libitum by bottle. Five groups of ten animals for each administrative route were used.
Since these compounds were insoluble in water, they were suspended in a 0.5% aqueous solution of carboxymethylcellulose at each dosage level. The administrative volume of each agent to 10 g body weight mouse was 0.2 ml for oral administration, while that to 100 g body weight of rat was 0.5 ml for intraperitoneal and oral administrations.
The LD50 values were calculated from the mortality on the eighth day by the Litchfield-Wilcoxon's method. The results of the tests were as tabulated below.
______________________________________                                    
N--(3',4'-dimethoxycinnamoyl)-anthranilic acid                            
Rats      1850       mg/kg        (o.)                                    
          2030       mg/kg        (o.)                                    
          385        mg/kg        (i.p.)                                  
          338        mg/kg        (i.p.)                                  
Mice      705        mg/kg        (o.)                                    
          500        mg/kg        (o.)                                    
N--(2'-chlorocinnamoyl)-anthranilic acid                                  
Mice      343        mg/kg        (o.)                                    
N--(4'-chlorocinnamoyl)-anthranilic acid                                  
Mice      551        mg/kg        (o.)                                    
N--(3'-chlorocinnamoyl)-anthranilic acid                                  
Mice      700        mg/kg        (o.)                                    
N--(2'-fluorocinnamoyl)-anthranilic acid                                  
Mice      321        mg/kg        (o.)                                    
N--(3'-fluorocinnamoyl)-anthranilic acid                                  
Mice      551        mg/kg        (o.)                                    
N--(4'-fluorocinnamoyl)-anthranilic acid                                  
Mice      481        mg/kg        (o.)                                    
______________________________________                                    
As demonstrated in Examples 8 , 9, 10 and 11, the new aromatic carboxylic amide derivatives and functional derivatives thereof of this invention serve to inhibit not only cutaneous anaphylaxie and release of chemical mediators from mast cells but also experiment asthmatic symptoms caused by an antigen-antibody reaction. These results obviously show that the derivatives of this invention are effective for the therapeutic treatment of allergic diseases including asthma, hay fever, .[.articaria.]. .Iadd.urticaria .Iaddend.and atopic dermatitis.

Claims (4)

    What is claimed is: .[.1. A compound selected from the group consisting of an aromatic carboxylic amide derivative of the formula:.]. ##STR12## .[.and therapeutically acceptable salts thereof, in which R1 and R2 are each a hydrogennatom or an alkyl group having 1-4 carbon atoms, R3 and R4 are each a hydrogen atom or together form another chemical bond, each X is a hydroxyl group, a halogen atom, an alkyl group having 1-4 carbon atoms and an alkoxy group having 1-4 carbon atoms, and n is an integer of 1-3, provided that when two X's are said alkyl or alkoxy groups, the alkyl groups thereof may be connected together
  1. into an alkylene group..]. .[.2. A compound of claim 1 selected from the group consisting of a nucleus-substituted cinnamic amide of the general formula:.]. ##STR13## .[.wherein R1, R2, X and n have the same meanings as given
  2. above, and therapeutically acceptable salts thereof..]. .[.3. A compound of claim 2 wherein both R1 and R2 are hydrogen atoms..]. .[.4. A compound of claim 2 wherein at least one of R1 and R2 is an alkyl group having 1-4 carbon atoms..]. .[.5. A compound of claim 1 selected from the group consisting of a nucleus-substituted phenylpropionamide of the general formula:.]. ##STR14## ps .[.wherein R1, R2, X and n have the same meanings as given
  3. above, and therapeutically acceptable salts thereof..]. .[.6. A compound of claim 5 wherein both R1 and R2 are hydrogen atoms..]. .[.7. A compound of claim 5 wherein at least one of R1 and R2 is an
  4. alkyl group having 1-4 carbon atoms..]. .Iadd.8. A compound comprising N-(3',4'-dimethoxycinnamoyl)-anthranilic acid. .Iaddend. .Iadd.9. A compound comprising N-(3',4'-dimethoxy-β-methylcinnamoyl)-anthranilic acid. .Iaddend. .Iadd.10. A compound comprising N-(3'-methoxy-4'-n-propoxycinnamoyl)-anthranilic acid. .Iaddend.
US05/802,486 1973-01-18 1977-06-01 Aromatic carboxylic amide derivatives Expired - Lifetime USRE32944E (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP48-7359 1973-01-18
JP735973A JPS5640710B2 (en) 1973-01-18 1973-01-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US05/434,252 Reissue US3940422A (en) 1973-01-18 1974-01-17 Aromatic carboxylic amide derivatives

Publications (1)

Publication Number Publication Date
USRE32944E true USRE32944E (en) 1989-06-06

Family

ID=11663750

Family Applications (2)

Application Number Title Priority Date Filing Date
US05/434,252 Expired - Lifetime US3940422A (en) 1973-01-18 1974-01-17 Aromatic carboxylic amide derivatives
US05/802,486 Expired - Lifetime USRE32944E (en) 1973-01-18 1977-06-01 Aromatic carboxylic amide derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US05/434,252 Expired - Lifetime US3940422A (en) 1973-01-18 1974-01-17 Aromatic carboxylic amide derivatives

Country Status (18)

Country Link
US (2) US3940422A (en)
JP (1) JPS5640710B2 (en)
AT (1) AT333726B (en)
BE (1) BE809935A (en)
BG (1) BG24538A3 (en)
CH (2) CH615152A5 (en)
DE (1) DE2402398C3 (en)
DK (1) DK139676C (en)
ES (1) ES422395A1 (en)
FI (1) FI60555C (en)
FR (1) FR2214476B1 (en)
GB (1) GB1446141A (en)
HU (1) HU168055B (en)
IT (1) IT1054151B (en)
NL (1) NL179370C (en)
NO (1) NO142441C (en)
SE (1) SE411117B (en)
SU (1) SU520041A3 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223639A (en) * 1989-11-06 1993-06-29 Kohjin Co., Ltd. Process for producing n-(3', 4'-dimethoxycinnamoyl)-anthranilic acid
US5545569A (en) * 1993-05-13 1996-08-13 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5733925A (en) 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6492547B2 (en) 2000-12-23 2002-12-10 Boehringer Ingelheim Pharma Kg Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US7625410B2 (en) 2001-05-02 2009-12-01 Boston Scientific Scimed, Inc. Stent device and method

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144250A (en) * 1973-05-14 1979-03-13 Stauffer Chemical Company Herbicidal active carboxanilide derivatives
JPS5830302B2 (en) * 1974-04-16 1983-06-28 キツセイヤクヒンコウギヨウ カブシキガイシヤ Shinki Hōkōzoku Carbon Sanamide Yudōtai no Seizō Hōhō
GB1484413A (en) * 1974-04-18 1977-09-01 Kissei Pharmaceutical Aromatic amidocarboxylic acid derivatives
DE2629752A1 (en) * 1976-07-02 1978-01-05 Boehringer Mannheim Gmbh NEW CARBONIC ACID DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
JPS56135454A (en) * 1980-03-26 1981-10-22 Kissei Pharmaceut Co Ltd Preparation of aromatic carboxylic acid amide derivative
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives
JPS5838244A (en) * 1981-09-01 1983-03-05 Kissei Pharmaceut Co Ltd Nuclear substituted cinnamoylanthranilate and its preparation
US4536346A (en) * 1983-05-06 1985-08-20 American Cyanamid Company Aralkanamidophenyl compounds
JPS6097946A (en) * 1983-11-01 1985-05-31 Ono Pharmaceut Co Ltd Carboxamide derivative, its production and remedy containing said derivative
JPS60116657A (en) * 1983-11-30 1985-06-24 Ono Pharmaceut Co Ltd Aniline derivative, its production, and remedy containing said derivative as active component
JPS60142936A (en) * 1983-12-28 1985-07-29 Ono Pharmaceut Co Ltd Substituted phenyl derivative, its preparation, and remedy containing it
JPS60146857A (en) * 1983-12-30 1985-08-02 Kissei Pharmaceut Co Ltd Alpha-haloaromatic amidocarboxylic acid derivative and antiallergic comprising it
JPS60146856A (en) * 1983-12-30 1985-08-02 Kissei Pharmaceut Co Ltd Alpha-haloaromatic amidocarboxylic acid derivative and antiallergic comprising it
IT1196348B (en) * 1984-11-29 1988-11-16 Italfarmaco Spa COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY
JPH078851B2 (en) * 1985-07-29 1995-02-01 鐘淵化学工業株式会社 3-phenylthiomethylstyrene derivative
JPH0733357B2 (en) * 1986-09-30 1995-04-12 日本レダリ−株式会社 Cinnamic acid derivative
JPH0692353B2 (en) * 1987-05-26 1994-11-16 マルコ製薬株式会社 Novel aminobenzoic acid amide derivative and method for producing the same
JP2617407B2 (en) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 Preventive and therapeutic agent for intimal cell hyperproliferative disease
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO1997029079A1 (en) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention
DE19935219A1 (en) 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Carboxamides, medicines containing these compounds, their use and manufacture
DE10065043A1 (en) * 2000-12-23 2002-07-04 Boehringer Ingelheim Pharma Carboxamides, medicines containing these compounds, their use and manufacture
EP1318141A1 (en) * 2001-12-04 2003-06-11 Dsm Nv Process for treating an aqueous medium containing phosphate, cyclohexanone and cyclohexanone oxime
CN1271046C (en) * 2001-12-04 2006-08-23 Dsmip财产有限公司 Method for processing water medium containing cylohexanone oxime and cyclohexanone
US7582657B2 (en) * 2001-12-10 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
NZ538663A (en) * 2002-08-29 2006-02-24 Univ Temple Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
DE10254872A1 (en) * 2002-11-25 2004-06-03 Symrise Gmbh & Co. Kg Anthranilic acid amides and their derivatives as cosmetic and pharmaceutical active ingredients
WO2005110392A1 (en) * 2004-05-14 2005-11-24 The University Of Melbourne Methods of modulating flt3 activity
JP2008526983A (en) 2005-01-14 2008-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Methods for modulating T cell functionality
ITMI20050261A1 (en) * 2005-02-21 2006-08-22 Carlo Ghisalberti STRUCTURAL ANALOGS OF AVENATRAMIDS THEIR USE IN USEFUL COMPOSITIONS IN THE TREATMENT OF DERMATOLOGICAL DISORDERS
ES2462925T3 (en) * 2006-06-14 2014-05-26 Symrise Ag Compounds with antimicrobial effect for the treatment of oral fetidity
EP1886662B1 (en) * 2006-06-14 2014-04-09 Symrise AG Anti-microbial compounds for treating bad breath
NZ574028A (en) 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
WO2008131481A1 (en) * 2007-04-26 2008-11-06 Fibrotech Therapeutics Pty Ltd Treatment of mesangioproliferative diseases
CN107162928B (en) * 2007-12-21 2022-03-11 塞尔塔医疗有限公司 Halogenated analogs of anti-fibrotic agents
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
EP2455077B1 (en) 2009-06-17 2014-06-11 National University Corporation Kumamoto University Prophylactic and/or therapeutic agent for dysmenorrhea
WO2011047432A1 (en) 2009-10-22 2011-04-28 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
DE102009046115A1 (en) * 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituted 3-phenylpropanoic acids and their use
WO2012102239A1 (en) * 2011-01-25 2012-08-02 三井化学アグロ株式会社 Process for production of aromatic amidecarboxylic acid derivative
US10188754B2 (en) 2013-05-16 2019-01-29 The Johns Hopkins University Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI)
CN104693063A (en) * 2015-03-18 2015-06-10 中国药科大学制药有限公司 Synthesis method of tranilast
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
CN110357789B (en) * 2018-04-11 2022-09-30 华东理工大学 N-substituted acrylamide derivative as DHODH inhibitor and preparation and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043868A (en) * 1959-12-09 1962-07-10 Searle & Co N-xenylalkanoylaminoalkanoic acids and esters thereof
US3488737A (en) * 1964-07-29 1970-01-06 Pfizer & Co C Novel beta-(substituted amino)propiophenones
US3636694A (en) * 1968-05-18 1972-01-25 Rhodiaceta Ag Apparatus and process for tangling fibers and filaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043868A (en) * 1959-12-09 1962-07-10 Searle & Co N-xenylalkanoylaminoalkanoic acids and esters thereof
US3488737A (en) * 1964-07-29 1970-01-06 Pfizer & Co C Novel beta-(substituted amino)propiophenones
US3636694A (en) * 1968-05-18 1972-01-25 Rhodiaceta Ag Apparatus and process for tangling fibers and filaments

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Kamarkar et al., J. Ind. Chem. Soc., vol. 30, pp. 689 694 (1953). *
Kamarkar et al., J. Ind. Chem. Soc., vol. 30, pp. 689-694 (1953).
Nossier et al, J. Chem. U.A.R., pp. 379 390 (1970). *
Nossier et al, J. Chem. U.A.R., pp. 379-390 (1970).
Nossier et al. J. Chem. U.A.R., vol. 72, #1, pp. 57-68 (1969).
Nossier et al. J. Chem. U.A.R., vol. 72, 1, pp. 57 68 (1969). *
Seka et al, Monatsh, 53 54, pp. 471 478 (1929). *
Seka et al, Monatsh, 53-54, pp. 471-478 (1929).

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223639A (en) * 1989-11-06 1993-06-29 Kohjin Co., Ltd. Process for producing n-(3', 4'-dimethoxycinnamoyl)-anthranilic acid
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6268390B1 (en) 1991-09-27 2001-07-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6074659A (en) 1991-09-27 2000-06-13 Noerx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6262079B1 (en) 1992-09-25 2001-07-17 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US8067022B2 (en) 1992-09-25 2011-11-29 Boston Scientific Scimed, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US20060029986A1 (en) * 1992-09-25 2006-02-09 Grainger David J Prevention and treatment of cardiovascular pathologies
US6599928B2 (en) 1992-09-25 2003-07-29 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5733925A (en) 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6569441B2 (en) 1993-01-28 2003-05-27 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6166090A (en) 1993-05-13 2000-12-26 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US20060135560A1 (en) * 1993-05-13 2006-06-22 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5545569A (en) * 1993-05-13 1996-08-13 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6358989B1 (en) 1993-05-13 2002-03-19 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US20020182659A1 (en) * 1993-05-13 2002-12-05 Neorx Corporation Method to determine TGF-beta
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US8097642B2 (en) 1995-02-15 2012-01-17 Boston Scientific Scimed, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US8158670B2 (en) 1995-02-15 2012-04-17 Boston Scientific Scimed, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6720350B2 (en) 1997-03-31 2004-04-13 Scimed Life Systems, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US6492547B2 (en) 2000-12-23 2002-12-10 Boehringer Ingelheim Pharma Kg Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof
US7625410B2 (en) 2001-05-02 2009-12-01 Boston Scientific Scimed, Inc. Stent device and method

Also Published As

Publication number Publication date
NO142441B (en) 1980-05-12
BG24538A3 (en) 1978-03-10
ATA44374A (en) 1976-04-15
CH615152A5 (en) 1980-01-15
DE2402398B2 (en) 1980-10-09
NO740137L (en) 1974-07-19
DE2402398A1 (en) 1974-08-08
SE411117B (en) 1979-12-03
JPS5640710B2 (en) 1981-09-22
NL179370C (en) 1986-09-01
CH613442A5 (en) 1979-09-28
ES422395A1 (en) 1976-08-01
GB1446141A (en) 1976-08-18
FR2214476B1 (en) 1977-08-12
IT1054151B (en) 1981-11-10
US3940422A (en) 1976-02-24
FI60555B (en) 1981-10-30
AU6461374A (en) 1975-07-17
NL179370B (en) 1986-04-01
HU168055B (en) 1976-02-28
DE2402398C3 (en) 1981-07-23
NL7400754A (en) 1974-07-22
BE809935A (en) 1974-05-16
FR2214476A1 (en) 1974-08-19
DK139676B (en) 1979-03-26
SU520041A3 (en) 1976-06-30
NO142441C (en) 1980-08-20
AT333726B (en) 1976-12-10
JPS4993335A (en) 1974-09-05
DK139676C (en) 1979-09-10
FI60555C (en) 1982-02-10

Similar Documents

Publication Publication Date Title
USRE32944E (en) Aromatic carboxylic amide derivatives
US4070484A (en) Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
US4026896A (en) Aromatic amidocarboxylic acids and pharmaceutical compositions thereof
US4277497A (en) Analgesic 2-(M-benzoylphenoxy)-propionic acid derivatives
EP0286364B1 (en) Substituted Di-t-Butylphenols
JPS6032620B2 (en) Novel cyanacetanilide derivative and its production method
US3349088A (en) Therapeutically valuable 1, 2-dihyro-1, 2, 4-benzotriazine derivatives and process for preparation thereof
US4510139A (en) Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
FI77227B (en) FOERFARANDE FOER FRAMSTAELLNING PHARMACOLOGICALLY ACTIVE 1-METHYL-5-P-TOLUOYLPYRROL-2-ACETIC AMRAIDE.
US4337270A (en) Novel anthranilic acid derivatives
Uenlue et al. Studies On Novel 7‐Acyl‐5‐Chloro‐2‐Oxo‐3H‐Benzoxazole Derivatives As Potential Analgesic And Anti‐Inflammatory Agents
CS267551B1 (en) Pharmaceutical agents for asthma treatment and method of effective substance production
US4515980A (en) Substituted aminobenzoates, their preparation and use
US2502451A (en) Amino-alkyl esters of diphenylamine 2-monocarboxylic acids
US3996279A (en) Novel 2-amino methyl-4,6-dihalogenphenol derivatives and methods for the preparation thereof
US4116972A (en) Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation
US3694489A (en) Pharmacologically active esters and amides of n-{8 3-trifluoromethylphenyl{9 -anthranilic acid
EP0227431A1 (en) Heterocyclic amides
US4269855A (en) (3-Alkylamino-2-hydroxypropoxy)-furan-2-carboxylic acid anilides and physiologically tolerated acid addition salts thereof and medicaments containing them
JP2011213718A (en) Manufacturing method of medicine containing amino acid derivative and derivative of the same
FI77246B (en) FREQUENCY REFRIGERATION FOR ANTI-ALLERGY 4H-FURO / 3,2-B / INDOLER.
US4624949A (en) Dibenzo[b,d]thiopyran derivatives, pharmaceutical composition and use
US4221814A (en) Terephthalic acid monoamide derivatives, process for preparing the same, and an anti-allergic agent prepared from the same
US4835180A (en) N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity
US3362993A (en) Substituted benzamides and methods for their preparation